Royalty Pharma plc (RPRX) |
|
36.03 -0.27 (-0.74%)
|
03-31 16:00 |
|
Open: |
36.28 |
Pre. Close: |
36.3 |
|
High:
|
36.32 |
Low:
|
35.955 |
|
Volume:
|
1,760,291 |
Market Cap:
|
15,967(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:48 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 44.6 One year: 52.09 |
| Support: |
Support1: 34.78 Support2: 32.68 |
| Resistance: |
Resistance1: 38.18 Resistance2: 44.6 |
| Pivot: |
35.26  |
| Moving Average: |
MA(5): 36.66 MA(20): 34.97
MA(100): 38.89  MA(250): 40.67 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 65.5 %D(3): 71.9 |
| RSI: |
RSI(14): 51.6 |
| 52-week: |
High: 44.75 Low: 32.68 |
| Average Vol(K): |
3-Month: 1,928 (K) 10-Days: 2,078 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RPRX ] has closed below upper band by 34.5%. Bollinger Bands are 67.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
36.37 - 36.63 |
36.63 - 36.82 |
|
Low:
|
35.28 - 35.63 |
35.63 - 35.9 |
|
Close:
|
35.55 - 36.02 |
36.02 - 36.38 |
|
Company Description |
|
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. |
Headline News |
Wed, 29 Mar 2023
Royalty Pharma plc (NASDAQ:RPRX) Given Average Rating of "Buy ... - MarketBeat
Mon, 27 Mar 2023
Royalty Pharma Announces 1 Billion Share Repurchase Program - Best Stocks
Mon, 27 Mar 2023
Royalty Pharma plc (RPRX) Stock: How Does it Score on Valuation Metrics? - InvestorsObserver
Thu, 23 Mar 2023
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million - Yahoo Finance
Thu, 23 Mar 2023
PureTech Health and Royalty Pharma Enter into KarXT Royalty ... - BioSpace
Tue, 21 Mar 2023
Robeco Institutional Asset Management B.V. Buys 30450 Shares of ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
441 (M) |
| Shares Float |
377 (M) |
|
% Held by Insiders
|
24.9 (%) |
|
% Held by Institutions
|
67.9 (%) |
|
Shares Short
|
7,100 (K) |
|
Shares Short P.Month
|
7,470 (K) |
Stock Financials |
|
EPS
|
1.92 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
13.48 |
|
Profit Margin (%)
|
22.5 |
|
Operating Margin (%)
|
41.9 |
|
Return on Assets (ttm)
|
3.3 |
|
Return on Equity (ttm)
|
8.5 |
|
Qtrly Rev. Growth
|
-2.1 |
|
Gross Profit (p.s.)
|
4.17 |
|
Sales Per Share
|
5.1 |
|
EBITDA (p.s.)
|
2.16 |
|
Qtrly Earnings Growth
|
36.2 |
|
Operating Cash Flow
|
2,060 (M) |
|
Levered Free Cash Flow
|
-1,480 (M) |
Stock Valuations |
|
PE Ratio
|
18.66 |
|
PEG Ratio
|
0.9 |
|
Price to Book value
|
2.67 |
|
Price to Sales
|
7.06 |
|
Price to Cash Flow
|
7.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2022-03-14 |
|
Ex-Dividend Date
|
2022-02-16 |
|
Your Ad Here
|
|
